Your email has been successfully added to our mailing list.

×
0 0 -0.0183861082737489 -0.041879468845761 -0.200715015321757 -0.175689479060266 -0.132788559754852 -0.132788559754852
Stock impact report

ArQule Announces Release of American Society of Hematology Abstract Detailing Results of the Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractor...

ARQULE (ARQL) 
Last arqule earnings: 10/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.arqule.com/investor-relations
Company Research Source: Business Wire
ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profileA total of 10 patients experienced partial responses (PRs) as of July 19th, the cutoff date for data included in the abstract, primarily at the higher doses: 7 with CLL/SLL, 1 with FL, 1 with Richter’s Transformation and 1 with DLBCL BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced the publication of the abstract highlighting data, as of July 19, 2019, from the phase 1 trial of ARQ 531, the company’s potent and reversible dual inhibitor of both wild type and C481-mutant Bruton’s tyrosine kinase (BTK), in patients with relapsed or refractory B-cell malignancies on the American Society of Hematology (ASH) website (link here). A poster containing the final data set from the phase 1 portion of this study will be presented at the ASH annual meeting in Orlando, FL on December 9, 2019 and will detail additional data with respect to ARQ 531’s safety pr Show less Read more
Impact Snapshot
Event Time:
ARQL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ARQL alerts
Opt-in for
ARQL alerts

from News Quantified
Opt-in for
ARQL alerts

from News Quantified